Saliva Collection and Diagnosis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Saliva Collection and Diagnosis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The saliva collection and diagnosis market are projected to register a CAGR of 10.1% during the forecast period (2022-2027).

COVID-19 has had a significant impact on the growth of the market, owing to the rising cases of infectious diseases among people and an increased preference for non-invasive and self-saliva-based tests. The increase in the need to diagnose COVID-19 infected patients created lucrative opportunities for the saliva collection and diagnosis market. For instance, according to the World Health Organization (WHO), in January 2022, the number of new COVID-19 cases increased by 5% across the globe from January 17th to January 23rd, 2022. Additionally, initiatives taken by the market players also contributed to the growth of the market. For instance, in December 2021, Cotipharma launched a saliva-based Omicron detecting PCR test in Africa. This test is CE-marked and can detect all known variants of SARS-CoV-2, including Omicron. Thus, COVID-19 is expected to have a significant impact on the growth of the market.

Furthermore, the increasing prevalence of infectious diseases among people across the globe is assumed to be one of the major driving factors for market growth. According to the World Health Organization (WHO), in 2021, 60% of the global population suffered from infectious diseases. The report also stated that infectious diseases kill over 17 million people a year, which illustrates the global burden of infectious diseases. The rise in the number of infectious cases has led to the demand for safe and effective diagnostic tests and products. Hence, saliva collection and diagnosis play a major role as a non-invasive diagnostic method for screening patients for several diseases.

Moreover, the increase in product approvals for saliva collection and diagnostic products is a significant factor likely to augment the market's growth. For instance, in July 2021, Hologic Inc.'s HOLX optima SARS-COV-2 molecular diagnostic test received CE marking by the European Union for its use with a saliva sample.

Additionally, the initiatives taken by the public authorities are also propelling the growth of the market. For instance, in August 2022, Australia launched one of the world's first preventative DNA screening programs for cancer and heart disease risk through free DNA saliva tests. It is a nationally collaborative project, led by Australia's Monash University. Furthermore, the initiatives taken by market players to support labs in conducting scientific studies using banked saliva samples, taking advantage of a sample type that is easy to access and non-invasive, are expected to have a positive impact on the growth of the market. For instance, in September 2021, Thermo Fisher Scientific launched the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit, which is designed to safely collect saliva for research. Such initiatives also contribute to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, the high cost of collection devices may impede the growth of the market.

Key Market TrendsThe Diagnostic Laboratories Segment is Expected to Hold a Major Market Share Over the Forecast Period

The diagnostic laboratories sub-segment by application is expected to drive the market's growth due to the increasing usage of saliva collection and diagnosis across laboratories. Factors contributing to the growth of the segment include the increasing prevalence of infectious and chronic diseases; ease of conduct; the growing number of standalone diagnostic laboratories as well as in-built diagnostic labs within healthcare settings; and the availability of skilled professionals.

The sudden outbreak of COVID-19 has increased the demand for saliva collection and diagnosis due to the surge in the number of infectious cases of COVID-19 disease across the world. Diagnostic laboratories play a crucial role in testing and diagnosing patients with COVID-19 and various other diseases owing to advanced equipment and quicker results, as a result of which, the segment is expected to project growth over the analysis period.

Moreover, the rising prevalence of chronic diseases such as cancer among people has led to the increasing use of non-invasive screening methods in diagnostic laboratories. For instance, the American Cancer Society's 2022 statistics estimated that about 54,000 new cases of the oral cavity or oropharyngeal cancer will be diagnosed in 2022 in the United States. Saliva collection and diagnosis is widely used in cancer diagnosis in diagnostic laboratories owing to its accuracy and painless procedure.

The launch of new products is also propelling the growth of the market segment. For instance, in June 2022, Goodbody Health Inc. launched four saliva tests that can determine a person's risk of getting cancer or heart disease over ten years via looking at genetics. Such launches are expected to propel the growth of the segment over the coming years.

Thus, owing to the abovementioned factors, the market segment is expected to project growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America is expected to hold a significant share in the market owing to the increasing prevalence of infectious diseases, growing preference for saliva tests, and the launch of newer products by the market players and others.

The increasing prevalence of chronic diseases in the United States contributes to the growing demand for saliva collection and diagnosis products. According to the American Cancer Society, 2022 statistics, it was estimated that in the United States there are about 38,700 males and 15,300 females living with oral and pharynx cancer. Similarly, according to statistics published by MedAlertHelp, in 2022, about 5% to 20% of Americans are diagnosed with influenza every year. Furthermore, according to the data published by the Centers for Disease Control and Prevention in October 2021, overall, 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits were reported in the 2019-2020 season. Such a growing burden of disease is creating demand for saliva collection and diagnosis, thus driving the growth of the market in the region.

Moreover, the launch of products is expected to drive the growth of the regional market. For instance, in August 2022, Viome Life Sciences launched CancerDetect, a diagnostic test for oral and throat cancer that uses mRNA technology and an AI-powered platform. Additionally, in September 2021, Thermo Fisher Scientific launched the SpeciMax Stabilized Saliva Collection Kit, which is designed to safely collect saliva for research. This kit preserves viral nucleic acids in a non-hazardous stabilization solution that inactivates common respiratory viruses.

Thus, owing to the abovementioned factors, the studied market in the region is expected to grow over the forecast period.

Competitive Landscape

The saliva collection and diagnosis market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Thermo Fisher Scientific, Neogen Corporation, Abbott, Sarstedt AG & Co.KG, Autogen, Inc., Oasis Diagnostics, Porex, Salimetrics, LLC, Takara Bio, Inc., Arcis Bio, Orasure Technologies, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.